PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 88 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $159,791 | -5.8% | 15,409 | +30.1% | 0.00% | 0.0% |
Q2 2023 | $169,635 | +100.7% | 11,846 | +0.1% | 0.00% | 0.0% |
Q1 2023 | $84,538 | -35.1% | 11,840 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $130,197 | +7.6% | 11,604 | +6.1% | 0.00% | 0.0% |
Q3 2022 | $121,000 | +33.0% | 10,933 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $91,000 | -33.6% | 10,778 | +7.2% | 0.00% | 0.0% |
Q1 2022 | $137,000 | -35.4% | 10,055 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $212,000 | -40.4% | 10,763 | -2.9% | 0.00% | -50.0% |
Q3 2021 | $356,000 | -7.3% | 11,085 | -2.3% | 0.00% | +100.0% |
Q2 2021 | $384,000 | +51.8% | 11,348 | +68.2% | 0.00% | 0.0% |
Q1 2021 | $253,000 | +22.2% | 6,747 | +8.0% | 0.00% | 0.0% |
Q4 2020 | $207,000 | -12.3% | 6,245 | -2.8% | 0.00% | 0.0% |
Q3 2020 | $236,000 | +9.3% | 6,424 | -2.2% | 0.00% | 0.0% |
Q2 2020 | $216,000 | +31.7% | 6,570 | +3.1% | 0.00% | 0.0% |
Q1 2020 | $164,000 | -21.9% | 6,370 | -5.5% | 0.00% | 0.0% |
Q4 2019 | $210,000 | – | 6,738 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |